Taysha Gene Therapies Investor Relations Material
Latest events
Q1 2025
Taysha Gene Therapies
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Taysha Gene Therapies Inc
Access all reports
Taysha Gene Therapies Inc. is a biotechnology company focused on developing gene therapies for the treatment of monogenic diseases of the central nervous system. The company leverages its adeno-associated virus (AAV) gene therapy platform to create treatments targeting rare genetic disorders, particularly those affecting the brain and spinal cord. Taysha's pipeline includes therapies aimed at conditions such as neurodegenerative and neurodevelopmental diseases, with a mission to provide life-changing treatments for patients with limited or no therapeutic options. The company is advancing its programs through research, clinical development, and regulatory processes. The company is headquartered in Dallas, Texas, and its shares are listed on the NASDAQ.
Latest articles
)
D. E. Shaw & Co: Inside the Quiet Giant of Quant Finance
A deep dive into D. E. Shaw's evolution from a $28M quant startup to a $65B hedge fund giant, built on research, computing, and quiet consistency.
2 Jul 2025
)
Pershing Square Capital Management: Conviction, Reinvention, and Contrarian Investing
Pershing Square Capital Management has grown into a top-tier hedge fund through reinvention, conviction, and focus on long-term value creation.
2 Jul 2025
)
Eli Lilly: The Pharma Giant Behind Mounjaro and Zepbound
Eli Lilly's journey from insulin pioneer to global pharma giant, leading innovation in diabetes, obesity, and the future of metabolic health.
30 Jun 2025
Ticker symbol
TSHA
Country
🇺🇸 United States